NASDAQ : QNTM
Quantum BioPharma Ltd. — Key statistics
Healthcare · Biotechnology · Canada
Last price 2.44 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 20.66M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 18.71M |
| Enterprise Value | 15.82M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 8.47M |
| Shares Outstanding | 8.47M |
| Shares Change (YoY) | +114.18% |
| Shares Change (QoQ) | +48.15% |
| Owned by Insiders (%) | 5.48% |
| Owned by Institutions (%) | 11.72% |
| Float | 8.00M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.27 |
| P/TBV Ratio | 5.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.20 |
| Quick Ratio | 0.48 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.81 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -621.46% |
| Return on Assets (ROA) | -51.84% |
| Return on Invested Capital (ROIC) | -135.35% |
| Return on Capital Employed (ROCE) | -202.02% |
| Weighted Average Cost of Capital (WACC) | 12.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.48M |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -80.04% |
| 50-Day Moving Average | 3.09 |
| 200-Day Moving Average | 3.86 |
| Relative Strength Index (RSI) | 30.91 |
| Average Volume (20 Days) | 132,402 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 519,981 |
| Short Previous Month | 361,097 |
| Short % of Shares Out | 6.14% |
| Short % of Float | 6.50% |
| Short Ratio (days to cover) | 2.62 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.31M |
| Pretax Income | -25.30M |
| Net Income | -25.16M |
| EBITDA | -11.78M |
| EBIT | -12.31M |
| Earnings Per Share (EPS) | -$5.35 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.86M |
| Total Debt | 963,314 |
| Net Cash | 2.89M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | 6.09M |
| Book Value Per Share | 1.05 |
| Working Capital | 1.66M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -5.49M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 530,511 |
| Net Borrowing | 1.20M |
| Free Cash Flow | -5.49M |
| FCF Per Share | -$0.65 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -114.18% |
| Shareholder Yield | -114.18% |
| Earnings Yield | -242.25% |
| FCF Yield | -26.77% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 15, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:65 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |